File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Stemness And Chemotherapeutic Drug Resistance Induced By Eif5a2 Overexpression In Esophageal Squamous Cell Carcinoma

TitleStemness And Chemotherapeutic Drug Resistance Induced By Eif5a2 Overexpression In Esophageal Squamous Cell Carcinoma
Authors
Issue Date2015
PublisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html
Citation
Oncotarget, 2015, v. 6 n. 28, p. 26079-26089 How to Cite?
AbstractEsophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies of the digestive tract in East Asian countries. Multimodal therapies, including adjuvant chemotherapy and neo-adjuvant chemotherapy, have become more often used for patients with advanced ESCC. However, the chemotherapy effect is often limited by patients' drug resistance. This study demonstrated that EIF5A2 (eukaryotic translation initiation factor 5A2) overexpression induced stemness and chemoresistance in ESCC cells. We showed that EIF5A2 overexpression in ESCC cells resulted in increased chemoresistance to 5-fluorouracil (5-FU), docetaxel and taxol. In contrast, shRNAs suppressing eIF5A2 increased tumor sensitivity to these chemotherapeutic drugs. In addition, EIF5A2 overexpression was correlated with a poorer overall survival in patients with ESCC who underwent taxane-based chemotherapy after esophagectomy (P > 0.05). Based on these results, we suggest that EIF5A2 could be a predictive biomarker for selecting appropriate chemo-treatment for ESCC patients and EIF5A2 inhibitors might be considered as combination therapy to enhance chemosensitivity in patients with ESCC.
Persistent Identifierhttp://hdl.handle.net/10722/222477
ISSN
2015 Impact Factor: 5.008
2015 SCImago Journal Rankings: 2.294
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYang, H-
dc.contributor.authorLi, XD-
dc.contributor.authorZhou, Y-
dc.contributor.authorBan, X-
dc.contributor.authorZeng, TT-
dc.contributor.authorZhang, BZ-
dc.contributor.authorYun, J-
dc.contributor.authorXie, D-
dc.contributor.authorGuan, X-
dc.contributor.authorLi, Y-
dc.date.accessioned2016-01-18T07:41:06Z-
dc.date.available2016-01-18T07:41:06Z-
dc.date.issued2015-
dc.identifier.citationOncotarget, 2015, v. 6 n. 28, p. 26079-26089-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/10722/222477-
dc.description.abstractEsophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies of the digestive tract in East Asian countries. Multimodal therapies, including adjuvant chemotherapy and neo-adjuvant chemotherapy, have become more often used for patients with advanced ESCC. However, the chemotherapy effect is often limited by patients' drug resistance. This study demonstrated that EIF5A2 (eukaryotic translation initiation factor 5A2) overexpression induced stemness and chemoresistance in ESCC cells. We showed that EIF5A2 overexpression in ESCC cells resulted in increased chemoresistance to 5-fluorouracil (5-FU), docetaxel and taxol. In contrast, shRNAs suppressing eIF5A2 increased tumor sensitivity to these chemotherapeutic drugs. In addition, EIF5A2 overexpression was correlated with a poorer overall survival in patients with ESCC who underwent taxane-based chemotherapy after esophagectomy (P > 0.05). Based on these results, we suggest that EIF5A2 could be a predictive biomarker for selecting appropriate chemo-treatment for ESCC patients and EIF5A2 inhibitors might be considered as combination therapy to enhance chemosensitivity in patients with ESCC.-
dc.languageeng-
dc.publisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html-
dc.relation.ispartofOncotarget-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleStemness And Chemotherapeutic Drug Resistance Induced By Eif5a2 Overexpression In Esophageal Squamous Cell Carcinoma-
dc.typeArticle-
dc.identifier.emailGuan, X: xyguan@hkucc.hku.hk-
dc.identifier.authorityGuan, X=rp00454-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.18632/oncotarget.4581-
dc.identifier.pmid26317793-
dc.identifier.scopuseid_2-s2.0-84944458774-
dc.identifier.hkuros256785-
dc.identifier.volume6-
dc.identifier.issue28-
dc.identifier.spage26079-
dc.identifier.epage26089-
dc.identifier.isiWOS:000363160100116-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats